Revolution in diagnosis? New blood test will detect cancer even before it develops

A new study published in Nature Medicine presents a blood test that identifies an RNA molecule associated with pre-cancerous changes in the fallopian tubes, with a sensitivity of 92.3% and specificity of 98.2%. The test is still in the research phase and is not clinically available.

A new study published in Nature Medicine presents a blood test that detects molecular signs of pre-cancerous changes in the fallopian tubes, even before an invasive tumor develops in ovarian cancer. The researchers, led by the Hoag Family Cancer Institute in California, identified an RNA molecule called Tu-Stroma, whose levels are elevated in the blood of women with STIC lesions – microscopic lesions considered precursors to high-grade serous ovarian cancer. In a validation group, the test identified 92.3% of women with a STIC lesion and 98.2% of healthy women. However, the test is still in the research phase and is not available for clinical use. The researchers plan prospective studies to validate the results. The article notes future potential for women at increased genetic risk but emphasizes that the test should not be used to delay recommended preventive surgery.